Metabolic Enzyme Could Be the Answer to Using Lynparza in Broad Range of Tumors

Metabolic Enzyme Could Be the Answer to Using Lynparza in Broad Range of Tumors
Cancer cells often change their metabolism to support their fast growing rate. Researchers have now found that an enzyme involved in this mechanism, called PGAM1, is also required to activate DNA repair in cancer cells. As a result, inhibiting PGAM1 could sensitize cancer cells to the FDA-approved ovarian cancer drug Lynparza (olaparib) and block tumor growth. The study

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *